Indaptus Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $171.9M
- Price
- $1.29
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.80%
- Volume
- 1.1M
About
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Quick stats
Shares outstanding133.2M
Computed float9.9M
Float / shares7.4%
Cash runway (months)6.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001857044
Websitehttps://indaptusrx.com
AI Summary
AI-generated1/5
criticalbearishearnings
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics announced the discontinuation of its Decoy20 combination study, confirming it has no participants remaining and currently no active clinical development programs while it evaluates strategic alternatives.
The company raised $12.0 million in gross proceeds via a private placement of 20 million shares at $0.60 per share, boosting total liquidity to approximately $11.6 million as of June 30, 2026.
Second quarter net loss narrowed to $1.8 million, or $0.02 per share, compared to a loss of $5.2 million in the prior year, driven primarily by an 83% reduction in R&D expenses following the discontinuation of clinical activities.
Red flags
- Lead clinical program Decoy20 discontinued; no active clinical development programs
- Massive dilution: shares outstanding increased from ~2.1M to ~133M (over 60-fold increase)
- Substantial doubt about ability to continue as a going concern cited in risk factors